U.S. FDA Approves Ustekinumab Biosimilar for Psoriasis, PsA
The U.S. Food and Drug Administration approved Biocon Biologics’ Yesintek, Bmab 1200 Biosimilar to ustekinumab (Stelara, J & J). Yesintek, a monoclonal antibody, is approved for the treatment of plaque psoriasis, psoriatic arthritis. Crohn’s disease, and ulcerative colitis. Biocon Biologics Ltd had previously announced that the Company had entered into a settlement and licensing agreement with Janssen Biotech Inc., […]